_	RFS		OS	
Variables	HR (95% CI)	P value	HR (95% CI)	P value
Age (> 65 vs. \leq 65)				
Gender (Female vs. male)				
Primary tumor site (Right-sided vs. Left-sided)				
Tumor grade (G3 vs. G1–2)	1.949(1.23-3.087)	0.004		
Pathological type (Mucinous vs. Non-mucinous)				
T-stage (T4 vs. Tis-3)			1.682(1.002-2.824)	0.049
N-stage (N1–2 vs. N0)	1.575(1.000-2.478)	0.050		
Preoperative CEA (> 200 vs. $\leq 200 \text{ ng/ml}$)				
Interval from primary tumor resection to liver metastases (> 12 vs. \leq 12 months)				
Number of metastases (> 1 vs. \leq 1)				
Size of the largest metastasis (> 5cm vs. \leq 5cm)	2.396(1.355-4.237)	0.003	3.849(1.852-7.997)	<0.001
Preoperative chemotherapy (Yes vs. no)	2.472(1.609-3.798)	<0.001		
Postoperative chemotherapy (Yes vs. no)				
Ablation (Yes vs. no)				
Soluble PD-L1 (High vs. low)	1.555(1.033-2.341)	0.034	2.219(1.197-4.112)	0.011


Supplementary Table 1. Multivariate analysis results of clinicopathological characteristics and preoperative soluble PD-L1.

Supplementary Table 2. Basic clinicopathological characteristics of patients in cohort

Variables	NO. of patients	Percent	
Age	puttentis		
>=65	6	12.24%	
<65	43	87.76%	
Gender			
Male	38	77.55%	
Female	11	22.45%	
Pathological grade			
G1–2	45	91.84%	
G3	4	8.16%	
Histological subtype			
Non-mucinous	42	85.71%	
Mucinous	0	0.00%	
Missing	7	14.29%	
Primary tumor T stage			
Tis-3	43	87.76%	
T4	5	10.20%	
Missing	1	2.04%	
Primary tumor N stage			
NO	16	32.65%	
N1-2	33	67.35%	
Primary tumor site			
Right-sided	12	24.49%	
Left-sided	37	75.51%	
Primary Tumor size			
\leq 5 cm	23	46.94%	
> 5 cm	5	10.20%	
Missing	21	42.86%	
Preoperative CEA			
\leq 200 ng/ml	48	97.96 %	
> 200 ng/ml	1	2.04%	
Interval from primary tumor resection metastases	on to liver		
\leq 12 months	41	83.67%	
> 12 months	8	16.33%	
Number of metastases per patient			
≤ 1	16	32.65%	
> 1	33	67.35%	
Size of the largest metastases			
\leq 5 cm	39	79.59%	
> 5 cm	10	20.41%	


Resection type of liver metastasis		
and primary tumor		
Simultaneous resection	22	44.9%
Staged resection	27	55.1%
Preoperative chemotherapy		
No	9	18.37%
Yes	40	81.63%
Chemotherapy	23	46.94%
Cetuximab-based	11	22.45%
Bevacizumab-based	6	12.24%
Postoperative chemotherapy		
No	4	8.16%
Yes	45	91.84%
Chemotherapy	34	69.39%
Cetuximab-based	9	18.37%
Bevacizumab-based	2	4.08%
CRS		
0–2	45	91.84%
3–5	4	8.16%

9 Supplementary Figures




11 Supplementary Figure 1. Flow chart of the enrollment process in cohort

14




Supplementary Figure 2. Characterization of isolated microvesicles. (A) 15 A representative TEM image of purified microvesicles from patients' 16 plasma. Scale bar, 500 nm.; (B) Characterization of isolated microvesicles 17 using nanoparticle tracking; (C) Representative immunoblots showing 18 expression of CD63, TSG101, Actinin-4 and Annexin A1 in plasma 19 microvesicles derived from six patients; (D) Representative immunoblots 20 showing expression of Actinin-4 and Annexin A1 in plasma microvesicles 21 and exosomes derived from five patients. 22





Supplementary Fig. 3. Preoperative exoPD-L1 and sPD-L1 improve 25 survival prediction when combine with CRS and can predict the prognosis 26 of patients with same CRS (0-2). ROC curve analysis of preoperative 27 exoPD-L1 or CRS or combination group at (A) 1-year RFS rate prediction 28 and (B) 3-year OS rate prediction; ROC curve analysis of preoperative 29 sPD-L1 or CRS or combination group at (C) 1-year RFS rate prediction 30 and (D) 3-year OS rate prediction; Kaplan–Meier estimates of (E) relapse-31 free survival (p=0.044) and (F) overall survival (p=0.37) in patients 32 according to preoperative exoPD-L1 in patients with low CRS (0-2); 33 Kaplan–Meier estimation of (G) relapse-free survival (p=0.038) and (H) 34 overall survival (p=0.0084) in patients according to preoperative sPD-L1 35 in patients with low CRS (0-2); Kaplan–Meier estimates of (I) relapse-free 36

survival (p=0.092) and (J) overall survival (p=0.0037) in patients
according to preoperative exoPD-L1 in patients with high CRS (3-5);
Kaplan–Meier estimation of (K) relapse-free survival (p=0.12) and (L)
overall survival (p=0.26) in patients according to preoperative sPD-L1 in
patients with high CRS (3-5).




44 Supplementary Fig. 4. Immunohistochemical detection of CD3, CD8,
45 PD1 and granzyme B expression at the tumor center (CT) and/or the





Supplementary Fig. 5. Both GB and PD1 expression at the invasive margin of colorectal liver metastases can be used as biomarkers of survival. Kaplan–Meier estimates of (A) relapse-free survival (p=0.023) and (B) overall survival (p=0.026) in patients according to GB expression at the invasive margin in colorectal liver metastasis; Kaplan–Meier estimates of (C) relapse-free survival (p=0.68) and (D) overall survival (p=0.024) in patients according to PD1 according to the expression of PD1 at the





58

59 **Supplementary Fig. 6.** ExoPD-L1 can be used as follow-up markers in 60 CRLM patients. (A-C) Concomitant imaging and circulating PD-L1 61 sampling as well as CEA results in three patients experiencing response 62 after preoperative chemotherapy, but disease progression (> 6 months) 63 after postoperative chemotherapy as observed in liver metastasis on MRI 64 or CT scan; (D-E) Concomitant imaging and circulating PD-L1 sampling

65	as well as CEA in two patients experiencing response after preoperative
66	chemotherapy, but early recurrence after postoperative chemotherapy as
67	observed in liver metastasis on MRI or CT scan. Tumor metastases in the
68	scans are indicated by arrows. R: Response to preoperative chemotherapy;
69	S: surgery of hepatectomy; PD: progression of disease.